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ABSTRACT: Among class A G protein-coupled receptors
(GPCR), the human adenosine A2A receptor (hA2AAR)
remains an attractive drug target. However, translation of
A2AAR ligands into the clinic has proved challenging and an
improved understanding of A2AAR pharmacology could
promote development of more efficacious therapies. Sub-
type-selective fluorescent probes would allow detailed real-
time pharmacological investigations both in vitro and in vivo.
In the present study, two families of fluorescent probes were
designed around the known hA2AAR selective antagonist
preladenant (SCH 420814). Both families of fluorescent
antagonists retained affinity at the hA2AAR, selectivity over all
other adenosine receptor subtypes and allowed clear visual-
ization of specific receptor localization through confocal imaging. Furthermore, the Alexa Fluor 647-labeled conjugate allowed
measurement of ligand binding affinities of unlabeled hA2AAR antagonists using a bioluminescence resonance energy transfer
(NanoBRET) assay. The fluorescent ligands developed here can therefore be applied to a range of fluorescence-based
techniques to further interrogate hA2AAR pharmacology and signaling.
■ INTRODUCTION
The adenosine receptors belong to class A of the G protein-
coupled receptor (GPCR) superfamily with the latter
accounting for about 30% of the molecular targets for currently
marketed drugs.1 The pharmacological profile of the adenosine
receptors is defined by the function of four adenosine receptor
subtypes, A1, A2A, A2B, and A3, each of which possess distinct
signaling and pharmacological properties.2 Among this family,
the adenosine A2A receptor (A2AAR) represents an attractive
drug target which has been the subject of intensive medicinal
chemistry research over the last 40 years.3,4 The A2AARs signal
primarily through GαS proteins in the periphery
2 but can also
signal through Gαolf in the striatum.
5 Upon receptor activation,
both Gs and Golf-coupled receptors act by stimulating adenylyl
cyclase leading to an increase of intracellular cAMP levels and
subsequent activation of a series of downstream signaling
cascades.6 Over 30 X-ray crystal structures for the hA2AAR
have been solved in complex with a range of molecules,
providing useful insights into the structural framework of this
membrane protein and helped the rational design and
development of selective hA2AAR ligands
7−11 for the treatment
of several diseases including cardiovascular, inflammatory, and
CNS disorders.12−14 More recently, blockade of the A2AAR
pathway has generated renewed interest because of the role of
adenosinergic signaling in cancer immunotherapy.15 In vitro
studies and animal models have shown that adenosine-
mediated activation of the high affinity A2AARs expressed on
the surface of immune cells suppresses the antitumor response
in the host, facilitating cancer growth and dissemination.16,17
Moreover, the expression of A2AARs correlates with the
malignancy of the tumor, suggesting these membrane-bound
proteins might be considered as a prognostic biomarker for the
severity of neoplastic disease.18 A number of small-molecule
A2AAR antagonists are currently being explored as novel
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therapeutics to inhibit this adenosine-mediated suppression of
the immune responses in patients with solid malignancies,
including nonsmall cell lung cancer, breast cancer, and prostate
carcinoma (Figure 1).
To date only two molecules targeting the A2AAR have
reached the market: Regadenoson (Lexiscan, Astellas Pharma),
a pharmacological stress agent for myocardial perfusion
injury12,19 and Istradefylline (NOURIANZ, Kyowa Kirin
Inc.), a xanthine-based hA2AAR antagonist which has reached
the market in Japan for treating the symptoms of Parkinson’s
disease (PD)20,21 However, despite the many therapeutic
opportunities associated with the A2AAR, translation of
adenosine ligands from the bench into the clinic has been
hampered by a lack of understanding of the tissue and cell-type
specific receptor pharmacology, leading to on-target side
effects.13 Additional knowledge on the function of the A2AAR
could be achieved through real-time monitoring of the
localization and function of the receptor at native expression
levels in specific human cell types in both health and disease,
with the aim of developing more selective and efficacious
therapies. Fluorescent ligands therefore represent useful tools
to achieve this aim as they offer the ability to study the target
receptor at endogenous expression levels, in real-time and,
importantly, in unmodified living cells.22
Fluorescent ligands for the ARs have been successfully
developed and have allowed various aspects of their
pharmacology, such as the signaling23,24 and dynamics,25,26
to be investigated. For example, the BODIPY 630/650-X-
labeled xanthine amine congener (XAC), developed in our
laboratories, allowed the quantification of specific A1AR−
antagonist complexes at the single molecule level in living cells
using fluorescence correlation spectroscopy (FCS).26 How-
ever, intracellular accumulation of the ligand observed over
extended incubation times through confocal microscopy, as
well as the promiscuous nature of the probe in binding other
adenosine receptors, restricted its use to recombinant cells.
Receptor-subtype selectivity is particularly important when
probing the A2AAR pharmacology in unmodified, endoge-
nously expressing tissues and cells, as other adenosine receptor
subtypes are often coexpressed.2,12 Jacobson and co-workers
pioneered the development of fluorescent probes selective for
the hA2AAR, including fluorescent analogues of the A2AAR
selective antagonist SCH442416 labeled with an Alexa Fluor
488 dye, that have been used successfully for fluorescence
polarization27 and flow cytometry28 assays. However, the
utility of these probes for bioimaging studies has not yet been
reported. This suggests there still remains the need to develop
additional selective hA2AAR probes, optimized for imaging
studies that would allow specific visualization of the hA2AAR at
the single cell level in healthy and diseased systems.
In the present study, we sought to expand the current
pharmacological toolkit for the hA2AAR by generating a more
Figure 1. Small molecule hA2AAR antagonists currently investigated
as single agents, or in combination with monoclonal antibodies, in
patients with solid tumors.
Figure 2. Molecular docking of preladenant to the crystal structure of the hA2aAR (PDB 4EIY) executed with Schrödinger’s Glide (Schrödinger
release 2018-3). The images were generated with PyMOL (version 2.2.0). Preladenant is shown in spheres colored magenta. The GPCR is shown
in ribbon colored cyan. The key residues are labeled and shown in sticks. A zoomed view of preladenant (shown in licorice) in the binding pocket is
depicted in the box with hydrogen bonding interactions depicted as dashed lines.
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versatile suite of fluorescent probes with regard to their
photochemical and physicochemical properties and areas of
potential application. Here, we report the design, synthesis,
and pharmacological evaluation of a novel series of subtype-
selective fluorescent ligands (12−17) for the human adenosine
hA2AAR receptor based upon preladenant (a high affinity
(hA2AAR Ki = 1.0 nM)
29 and highly selective (hA1, hA2B and
hA3 Ki > 1000 nM)
29 hA2AAR antagonist), which are amenable
to use in a variety of fluorescence-based techniques. These
A2AAR selective fluorescent ligands will be valuable tools for
the wider scientific community for both in vitro and in vivo
applications and high-resolution imaging studies into the role
of A2AAR in health and disease.
■ RESULTS AND DISCUSSION
Design Strategy. Our synthetic strategy commenced by
exploring the existing structure−activity relationships
(SAR)4,30−32 of the selected parent drug preladenant in
binding to the A2AAR to identify the optimal position of the
molecule that would be relatively insensitive to structural
modifications and allow fluorophore attachment without
affecting the original pharmacological properties of the ligand.
This preliminary screening was complemented through in
Scheme 1. Synthesis of the Fluorescent hA2A AR Antagonists
a
aReagents and conditions: (a) 2-furoic hydrazide, NEt3, dry THF, reflux; (b) 2-hydroxyethylhydrazine, CH3CN/H2O, reflux; (c) POCl3, ZnBr2,
80 °C for 5 h, 11% over three steps; (d) TsCl, DIPEA, DMAP 5%mol, DCM, 86%; (e) CbzCl, K2CO3, DMF, 66%; (f) K2CO3, CH3CN, 100 °C for
6 h, 40% (g) H2, Pd/C, EtOH, 82%; (h) 4, DIPEA, DMF, 80 °C, 20% (i) 4 N HCl in dioxane, RT, quantitative; (j) 12-14-15-16-17 fluorophore-
NHS, DIPEA, DMF, RT,97%, quantitative; 13 BODIPY carboxylic acid, HATU, DIPEA, DMF, 96%.
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silico studies which were undertaken to rationalize the possible
binding interactions established between the parent ligand and
the hA2AAR (Figure 2).
Molecular docking simulations of preladenant to the 1.8 Å
resolution crystal structure (PDB 4EIY) of the hA2AAR
9
revealed the core pyrazolo[4,3-e][1,2,3]triazolo[1,5-c]-
pyrimidin-5-amine (PTP) scaffold interacts with key receptor
residues in an equivalent fashion to the antagonist ZM241385,
including polar contacts with Asn253 and Glu169 and a π-
stacking interaction with Phe168.7,9 The side chain of
preladenant adopted a conformation extending toward
extracellular loop 3 (ECL3) and, therefore, to a more
solvent-exposed region of the GPCR. These results were
further validated by previously reported SAR studies, which
showed that modifications at the extended methoxyethyl ether
moiety were well tolerated.4,30,31,33 Thus, it seemed logical to
exploit this side chain of preladenant as a flexible point to
explore linker/fluorophore elaboration. We hypothesized that
an amino alkyl spacer would provide sufficient spatial
separation between the fluorophore and the orthosteric
binding moiety. When designing fluorescent probes the
introduction of a spacer between the parent pharmacophore
and the fluorophore is often included in the design strategy
and the nature and the length of the linker, and the
fluorophore itself can significantly influence the final
pharmacological profile of the fluorescent conjugate.34,35
Structural modifications must be performed at specific
positions, which can be easily tolerated and do not cause
significant impact upon pharmacological activity. Therefore,
we undertook modification of the methoxy tail of the parent
compound preladenant by conjugation with an amino alkyl
spacer, leading to the corresponding amino functionalized
congener amenable to conjugation with a series of
commercially available fluorophores (Scheme 1). This novel
series of fluorescent ligands included probes featuring the 4,4-
difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY) dyes along-
side water-soluble dyes such as sulfonated cyanine-5 (sulfo-
Cy5) and Alexa Fluor 647 fluorophores. These probes were
selected on the basis of several considerations. For example,
the use of fluorophores with long-wavelength excitation/
emission spectra is preferred as it minimizes the degree of
overlap with background autofluorescence in living
cells.23,35−38 The BODIPY fluorophores embody the first
choice for fluorescent derivatization given their stability and
photochemical properties.39 The 6-(((4,4-difluoro-5-(2-thien-
yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)styryloxy)acetyl)-
aminohexanoic acid (BODIPY630/650) is often the favored
among this family of dyes due to its advantageous spectral
profile (excitation 630 nm, emission 650 nm). It has been
previously suggested that given the lipophilic nature of the
probe, the BODIPY moiety is likely to reside within the
membrane bilayer. Indeed, this fluorophore has been shown to
be heavily quenched in aqueous solution, therefore the optimal
location would be in a lipid environment as this reduces
background fluorescence from nonbound ligand, which is
particularly advantageous for imaging studies.34 However, the
intrinsic lipophilic nature of these dyes may limit their
applicability in vivo due to the reduced stability in the
bloodstream as well as limited detection after IV admin-
istration.40 One possible strategy to overcome these issues is by
employing water-soluble fluorophores such as those belonging
to the Cy5 and Alexa Fluor families of dyes. These water-
soluble dyes also possess good photochemical properties and
have therefore been particularly advantageous for the develop-
ment of in vivo probes such as in cancer imaging.41
Synthesis of the Fluorescent hA2AAR Antagonists. On
the basis of the information obtained from the molecular
docking studies, a novel series of fluorescent antagonists for the
hA2AAR receptor were synthesized featuring BODIPY-, Cy5-,
and AF647-based probes. The general route to the desired
probes is illustrated in Scheme 1.
The synthesis comprised 10 steps to a common precursor
from which six different fluorescent analogues were generated.
First, a one-pot procedure reported by Kuo et al.42 for the
synthesis of intermediate 4 was followed. This involved
reaction of commercially available 2-amino-4,6-diclhoropyr-
imidine-5-carbaldehyde (1) with 2-furoic hydrazide in
anhydrous THF in the presence of Et3N under reflux for 2 h
to obtain 2 via nucleophilic aromatic substitution (SNAr).
Once the desired product was formed, solvent was removed in
vacuo and a solution of 2-hydroxyethylhydrazine in a mixture
of CH3CN/H2O was added to the crude product to displace
the chlorine at the 2-position through SNAr and afforded
compound 3 after ring rearrangement. Thereafter, 3 was
cyclized in the presence of a catalytic amount of ZnBr2 and an
excess of POCl3.
This dehydrative cyclization occurred with concomitant
Dimroth rearrangement43,44 to afford intermediate 4 in a
disappointing overall yield (11% over three steps). Mass
spectroscopy and 1H NMR showed that the desired product
afforded was a 2:1 mixture of chloride and bromide derivatives:
one single peak at tR = 2.50, M + H
+ = 304 (4a) and M + H
+ =
348 (4b); in the
1H NMR analysis the peaks characteristic of
the aromatic region of the spectra were in common to both.
Conversely, the peaks characteristic of the alkyl halide tail
appeared in the spectra with different chemical shifts for both
bromide and chloride derivatives: peaks at 4.66 ppm (t, J = 6.2
Hz, 1H, −CH2Br), 4.60 ppm (t, J = 5.9 Hz, 2H, −CH2Cl),
4.09 ppm (t, J = 5.9 Hz, 2H, −CH2CH2Cl), 3.94 ppm (t, J =
6.2 Hz, 1H, −CH2CH2Br).
Subsequently, synthesis of the amino functionalized tail of
the final molecule started by activating the hydroxyl group of
commercially available 5 with tosyl chloride in DCM to afford
6. Under basic conditions, commercially available 1-(4-
hydroxyphenyl) piperazine 7 was protected at the free
secondary amino group with benzyl chloroformate to afford
the corresponding benzylcarbamate-protected piperazine de-
rivative 8 with reasonable yield (66%). Under basic conditions,
nucleophilic displacement of the tosyl group of 6 by the
phenolic hydroxyl of 8 afforded the diprotected intermediate 9.
This allowed selective removal of the two protecting groups
employing different conditions: hydrogenolysis of the
benzylcarbamate group in the presence of 10% palladium-on-
carbon (Pd/C) gave the corresponding free secondary amine
in quantitative yield. Under basic conditions, substitution of
the primary ethyl halide tail of compound 4 by the nucleophilic
piperazine nitrogen afforded compound 10, which underwent
acidolytic Boc deprotection to generate the corresponding
amine 11 as its di-HCl salt. Finally, 11 was coupled with the
appropriate commercially available BODIPY, Cy5, and AF647
succinimidyl esters and to a BODIPY 630/650 carboxylic acid
(13) synthesized in our laboratory45 to afford a focused library
of six fluorescent analogues (12−17).
The novel fluorescent conjugates were isolated and purified
by reverse-phase high performance liquid chromatography
(RP-HPLC). The final purity of the fluorescent ligands was
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confirmed by analytical RP-HPLC with dual wavelength
detection and were determined as being ≥96% homogeneous.
Additionally, the chemical identity of probes (12−17) was
confirmed by high resolution mass spectrometry (HRMS)
(TOF ES+ and ES−).
Pharmacological Evaluation of the Fluorescent
hA2AAR Antagonists. The novel preladenant-based fluores-
cent ligands were assessed in a variety of pharmacological
assays. First, the novel compounds were validated through a
bioluminescence resonance energy transfer (BRET)46,47 ligand
binding assay, a proximity assay (<10 nm) that exploits the
energy transfer between the donor bioluminescent protein
nanoluciferase (NanoLuc)48 tagged to the receptor of interest
at its N-terminus (NanoLuc-A2AAR) and an acceptor
fluorescent molecule. For all of the fluorescent ligands used
in the present study, a clear saturable component of specific
binding could be detected (Table 1 and Figure 3) to the
hA2AAR that was associated with low levels of nonspecific
binding across all of the concentrations of fluorescent ligands
measured.
The novel fluorescent conjugates were able to bind to the
hA2AAR with good affinity. However, the affinity values
measured for the water-soluble probes were slightly lower
than the BODIPY conjugates (Table 1). A possible explanation
of the differences in binding affinity values among the two
groups of fluorescent ligands could be attributed to the
fluorophores employed, considering they constituted the only
structural difference between the compounds. It is possible that
the boron dipyrromethene scaffold of the BODIPY-labeled
hA2AAR fluorescent antagonists engages in a cooperative
fashion with key residues in an additional pocket of the
receptor,28 thereby contributing to increase the binding affinity
of the ligands. Conversely, due to the more hydrophilic nature
of the cyanine5 and AF647-bearing probes, it is possible that
these dyes are likely to be extending toward the extracellular
medium without engaging to key residues. This hypothesis is
consistent with previous work from our laboratories in which it
has been demonstrated that the selective A3 fluorescent
conjugate bearing a Cy5 moiety displayed 300-fold lower
affinity compared to the corresponding BODIPY630/650
conjugate with the same pharmacophore and linker, suggesting
that the BODIPY fluorophores directly contribute in
enhancing the binding affinity of ligands.23,28,35
Differences in the BRET ratio observed can be attributed to
a variety of factors (Figure 3). For example, when using green-
emitting ligands (excitation 503 nm, emission 512 nm) a
greater contribution from the NanoLuc emission spectra
(emission peak 462 nm) is detected in the green acceptor
emission channel (535 nm), leading to an increase in the
BRET ratio. Conversely, with red-shifted ligands the
contribution of the NanoLuc emission is markedly reduced
in the red acceptor channel and this leads to a reduction in the
background BRET ratio.46 The distance and the specific
orientation of the acceptor fluorophore with respect to the
donor NanoLuc can also influence the efficiency of the energy
transfer between the two species and contribute to the absolute
differences in the BRET ratio observed.49
Achieving A2AAR selectivity represents one of the major
objectives of our study, especially when the fluorescent ligands
are being developed with the intention of being applied to a
variety of fluorescence-based techniques in different tissues and
animal models endogenously expressing other adenosine
receptor subtypes. The NanoBRET saturation ligand binding
assay allowed us to determine the binding affinity of each
fluorescent A2AAR antagonist in HEK293 cells stably
expressing either the NanoLuc-A1, NanoLuc-A2B, or the
NanoLuc-A3 ARs. The results revealed that no specific binding
of the fluorescent ligands was detectable at the A1, A2B, and
A3AR subtypes at concentrations tested (Figure 4).
Given the higher affinity displayed at the A2AAR, the
BODIPY-labeled ligands were selected to assess whether the
novel synthesized probes were able to retain the functional
antagonistic ability of the parent compound preladenant. This
was performed using a previously described CRE-SPAP
reporter gene assay50 in CHO cells expressing the human
adenosine hA2AAR receptors. All the BODIPY-labeled ligands
were able to inhibit adenosine-5-N-ethylcarboxamide
(NECA)-mediated increase in SPAP production in a
competitive fashion, causing a rightward shift of the NECA
response curve as shown in Figure 5. From these data, it was
possible to perform Schild regression analysis and estimate the
affinity of each compound as shown in Table 2.
The fluorescent ligands largely retained their functional
antagonism as compared to the parent compound preladenant.
Moreover, when comparing fluorescent ligands bearing a short
linker (see Scheme 1), no significant difference in the
measured functional affinity was observed (p > 0.05,
comparing compounds 13 and 15, unpaired t test).
Conversely, when comparing fluorescent ligands containing a
longer linker the BODIPY 630/650 conferred 20-fold increase
in affinity to the congener (p < 0.05, comparing compounds 12
and 14, unpaired t test). In this pharmacological assessment,
compound 12 was the most potent of the series (pA2 = 9.31 ±
0.38, Figure 5A and Table 2). Interestingly, the affinity values
measured via the NanoBRET saturation ligand binding assay
(Table 1) were significantly lower compared to the affinity
values obtained in CRE-SPAP gene-reporter assay (Table 2).
The discrepancy in the affinity values is most likely due to the
different host cell type and species (hamster versus human)
employed in the two assays (CHO cells for CRE-SPAP and
HEK293G cells for NanoBRET), the assay configuration (e.g.,
the influence of the furimazine substrate for NanoLuc) as well
as the influence of the tag used in the NanoBRET experiments
(transiently expressed NanoLuc-hA2AAR for NanoBRET and
stably expressed wild-type hA2AAR for CRE-SPAP).
51
However, it is important to note that a small reduction in
Table 1. Binding Affinities of the Novel Fluorescent Ligands
Determined in Whole HEK293G Cells Transiently
Expressing the NanoLuc-hA2AAR
compd pKD (log M)
a n
12 (BY630/650-X) 7.39 ± 0.05 5
13 (BY630/650) 7.39 ± 0.02 4
14 (BY-FL-X) 7.77 ± 0.06 4
15 (BY-FL) 7.65 ± 0.10 5
16 (Sulfo-Cy5) 7.08 ± 0.09 5
17 (AF647) 7.22 ± 0.05 5
apKD value was calculated from the negative logarithm of the
equilibrium dissociation constant (KD) determined from saturation
ligand binding assay using increasing concentration of labeled ligand
in the absence or presence (to determine nonspecific binding) of
unlabeled ligand preladenant (1 μM). Data are expressed as mean ±
SEM of n experiments, where each experiment was performed in
triplicate.
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binding affinity of the fluorescent probe is not necessarily
detrimental as long as the probe binds to the targeted receptor
with sufficient specificity.52
Measuring the binding kinetics of a drug candidate is
becoming extremely relevant considering the emerging concept
that the rates at which a drug binds to its molecular target (kon)
and dissociates from it (koff) may be considered more valuable
parameters for predicting the effectiveness of a drug candidate
in vivo.53,54 In this regard, the BODIPY630/650-X-labeled
analogue 12 was selected to be screened for its kinetic profile
through a time-resolved fluorescence energy transfer (TR-
FRET)55−58 assay in membrane preparations from SNAP-
tagged-hA2AAR-HEK293 cells (Figure 6). TR-FRET is a
methodology which exploits proteins labeled with lanthanides
(e.g., terbium) as donor fluorophores. Lanthanides display a
long emission lifetime which allows for a time delay of the
measurements between the excitation and the fluorescence of
the acceptor fluorophore. This increases the sensitivity of the
assay due to a reduction of the short-lived background
fluorescence.52,55,58 The TR-FRET technology allowed us to
monitor the binding kinetics of 12 by measuring the observed
association constant (Kobs) at four different concentrations of
Figure 3. NanoBRET saturation binding curves measured in HEK293G cells transiently expressing the NanoLuc- hA2AAR for (a) 12, (b) 13, (c)
14, (d) 15, (e) 16, and (f) 17 in the presence (open circles) and absence (closed circles) of 1 μM preladenant. The graphs depicted are
representative of n = 5 (a, d, e, and f) or n = 4 (b,c) separate experiments. Each data point represents the mean value ± SEM performed in triplicate
in a single experiment.
Journal of Medicinal Chemistry Article
DOI: 10.1021/acs.jmedchem.9b01856
J. Med. Chem. 2020, 63, 2656−2672
2661
fluorescent ligand over a period of 1 h. The specific FRET
signal was obtained by subtracting the nonspecific signal
(determined in the presence of 10 μM ZM241385) from the
total signal at each time point. The kinetic parameters kon = 2.4
± 0.3 × 106 M−1 min−1, koff = 0.029 ± 0.004 min
−1, pKD = 7.91
± 0.06, and the residence time (1/koff) Tr = 35.36 ± 4.11 min,
n = 5 were then calculated by globally fitting the resulting
FRET data. This study revealed that fluorescent conjugate 12
has a relatively rapid on-rate but once bound dissociates slowly.
In addition, from the 60 min time point we were also able to
plot an equilibrium saturation curve of 12 and directly measure
the equilibrium dissociation constant (KD = 15.47 ± 1.92 nM,
Supporting Information, Figure S2) which was comparable to
the value obtained from the kinetic analysis fit.
Interestingly, we found that the binding affinity pKD of 12
measured in this kinetic study (7.91 ± 0.06) in HEK293G cell
membranes was similar to the pKD (7.39 ± 0.05) measured in
the same cells in NanoBRET experiments. These data suggest
that the large difference in observed binding affinity for 12
between NanoBRET experiments in HEK293G cells and CRE-
SPAP functional experiments in CHO-K1 cells is largely due to
the host cellular environment. Having established that the
novel fluorescent probes retain functional activity and binding
affinity at the hA2AAR, we next evaluated their utility for
confocal microscope imaging studies. Ideally, the novel
fluorescent ligands should bind specifically to the A2AAR
receptors on the cell surface and show both low levels of
nonspecific binding and diffusion into the cell cytosol. From
the BODIPY-labeled probes, we selected compounds 12 (red-
emitting) and 15 (green-emitting) (Scheme 1) and deter-
mined whether the selected compounds were suitable for
visualization of receptors in live cells. To this end, confocal
Figure 4. Specific binding of the novel fluorescent ligands at each subtype of adenosine receptor. The selectivity profiling of compound 12 (a), 13
(b), 14 (c), 15 (d), 16 (e), and 17 (f) is depicted by showing only the specific binding at each adenosine receptor subtype. For each compound,
the specific binding at each adenosine receptor was obtained by subtracting the nonspecific binding component from the total binding derived from
saturation binding experiments (see Figure 1 and Table 1). Nonspecific binding was defined in the presence of 1 μM preladenant for NanoLuc-
A2AAR, 10 μM DPCPX for NanoLuc-A1, 10 μM MRS1220 for NanoLuc-A3, and 10 μM PSB603 for NanoLuc-A2B, respectively. The graphs shown
above are representative of n = 4 (c,d) and n = 5 (a, b, e, and f) experiments, and the data are mean ± SEM of triplicate determinations in a single
representative experiment.
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microscopy was conducted on HEK293 cells expressing the
SNAP-tagged hA2AAR (Figure 7). The images captured with
the confocal microscope revealed that both compounds 12 and
15 bound specifically to the SNAP-tagged hA2AAR shown by
the high level of fluorescence localized at the cell membrane.
Preincubation with 1 μM of unlabeled antagonist ZM241385
produced a significant reduction of the fluorescence intensity
and very little intracellular fluorescence was observed. This
demonstrated that binding of both compounds was specific at
the SNAP-tagged hA2AAR as it was surmounted by high
concentration of unlabeled hA2AAR antagonist.
Figure 5. Inhibition of NECA-stimulated SPAP-secretion by the antagonists 12 (a), 13 (b), 14 (c), and 15 (d). CHO CRE-SPAP cells expressing
the human A2A receptor were stimulated with a concentration range of the agonist NECA in the absence and presence of the fluorescent antagonist
of interest (1, 10, and 100 nM for 12 and 15; 10, 100, and 1000 nM for 13 and 14). Data have been expressed as a percentage of the SPAP
production in response to serum-free media (0%) and to 1 μM forskolin (FSK, 100%). The data shown represent the combined mean ± SEM of n
= 7 (a), n = 6 (b,d) and n = 5 (c) experiments, where each experiment was performed in triplicate.
Table 2. pA2 Values of the BODIPY-Labeled Fluorescent
Ligands
compd hA2AAR pA2
a n
12 (BY630/650-X) 9.31 ± 0.38*† 7
13 (BY630/650) 8.61 ± 0.30 6
14 (BY-FL-X) 7.91 ± 0.26* 5
15 (BY-FL) 8.40 ± 0.26† 6
aAffinity of the BODIPY-labeled fluorescent ligands. Ability for these
ligands to inhibit the NECA-stimulated CRE-SPAP response in CHO
cells expressing the hA2AAR. Data are mean ± SEM for n separate
experiments performed in triplicate (statistical significance was
defined as *p < 0.05 unpaired t test comparing 12 and 14. †p <
0.05 unpaired t test comparing the binding affinity of 12 and 15
measured in CRE-SPAP assay and the NanoBRET assay).
Figure 6. TR-FRET association kinetic curve of specific 12 binding to
terbium-labeled SNAP-tagged-hA2AAR-HEK293 cell membranes at
37 °C. Cell membranes were treated with the indicated concentration
of fluorescent ligand, and the FRET signal was monitored every 30 s
for 1 h. Nonspecific binding was determined in the presence of 10 μM
ZM241385. The graph presented is a representative of n = 5
experiments performed in triplicate.
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We also investigated whether the water-soluble hA2AAR
fluorescent ligands were able to allow receptor visualization
through confocal imaging. The results revealed that probes 16
and 17 bind to the SNAP-tagged hA2AAR as demonstrated by
the high degree of fluorescence observed at the cell membranes
(Figure 8). Most importantly, the binding of the two ligands to
the A2AAR was highly specific as preincubation with 1 μM
ZM241385 completely inhibited the binding of each
fluorescent ligand. Very little nonspecific binding was detected,
and rewardingly, no measurable uptake of these ligands into in
the cytosol could be seen.
Compound 17 was selected for further studies. In particular,
the utility of Alexa Fluor 647-bearing probe 17 in measuring
the binding affinities of unlabeled hA2AAR antagonists was
Figure 7. Live cell confocal imaging of 12 (10 nM) and 15 (30 nM) binding to SNAP-tagged hA2AAR HEK293 cells in the absence or presence of
1 μM of unlabeled antagonist ZM241385. Cells were incubated at 37 °C with BG-Alexa Fluor 488 when imaging red-shifted ligands (12) or BG-
Alexa Fluor 647 to label the SNAP-tag on the N-terminus of the receptor when imaging green-shifted ligands (15) (middle frames). Images are
representative of images captured in three separate experiments (scale bar: 20 μm).
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investigated using the NanoBRET competition ligand binding
assay. HEK293 cells transiently expressing the NanoLuc-
hA2AAR were incubated with 17 (50 nM) and increasing
concentrations of the hA2AAR antagonists ZM241385,
SCH58261, SCH442416, and MRS1334, a selective adenosine
A3AR antagonist which was used as negative control. A
concentration dependent decrease of the BRET signal was
observed for the A2AAR selective compounds, allowing the
binding affinities of the unlabeled antagonists to be measured
(Figure 9 and Table 3). The values obtained through
fluorescent binding assays were comparable to the reported
literature values (R2 = 0.97, Supporting Information, Figure
S1) measured in radioligand binding experiments.4,59 No
concentration-dependent decrease of the BRET signal was
observed in the presence of the selective A3AR antagonist
Figure 8. Live cell confocal imaging of 16 (30 nM) and 17 (30 nM) binding to SNAP-tagged hA2AAR expressed in HEK293 cells. Cells were
incubated 30 min at 37 °C with BG-Alexa Fluor 488 prior incubation in the absence or presence of 1 μM ZM241385. Subsequently, cells were
incubated with 30 nM fluorescent ligand for 30 min at 37 °C prior to imaging. The images generated are from one single experiment and are
representative of three different experiments. The images were all captured using the same settings for laser power and detector gain. Scale bars are
50 μm.
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MRS1224, confirming the specificity of the binding of the
probe 17 to the A2AAR.
■ CONCLUSION
In the present study, we have reported the successful design,
development, and pharmacological evaluation of a novel series
of hA2AAR fluorescent antagonists, encompassing BODIPY-
bearing probes and water-soluble Cy5-labeled and AF647-
labeled probes, based on the high affinity and selective
preladenant scaffold. In particular, derivatization of the amino
functionalized congener 11 with two families of fluorescent
tags led to six hA2AAR fluorescent antagonists with retained
affinity and, most importantly, selectivity at the A2AAR subtype.
Both families of compounds allowed visualization of A2AARs
expressed in live cells as demonstrated by the high fluorescence
intensity at the cell membranes. The binding of these
fluorescent ligands could be surmounted by a high
concentration of ZM241385, confirming that the binding of
the probes was specific. Very little nonspecific binding was
observed for the water-soluble fluorescent antagonists (Figure
8). Within the water-soluble family of probes, fluorescent
conjugate 17 was selected to successfully monitor ligand
binding of reported hA2AAR antagonists (Figure 9 and Table
3).
The novel hA2AAR fluorescent ligands developed can be
broadly applied in a series of fluorescence-based techniques to
study the signaling and dynamics of the adenosine A2AAR
receptors in their native cellular environment spanning from in
vitro to in vivo applications. Most importantly, we believe that
these ligands in combination with the NanoBRET approach
and bioimaging studies can help to shed light on the
complexity of the A2AAR signaling in different biological
elements and during disease progression. This ultimately
should provide useful insights concerning specific A2AAR-
engagement in several disease phenotypes, including can-
cer.13,61,62
■ EXPERIMENTAL SECTION
Chemistry: Materials and Methods. Chemicals and solvents of
analytical and HPLC grade were purchased from commercial
suppliers and used without further purification. BODIPY630/650-X-
SE, BODIPY-FL-X-SE, and BODIPY-FL-SE were purchased from
Molecular Probes (Thermo Fisher Scientific). Alexa Fluor 647 NHS
ester was purchased from Thermo Fischer Scientific and sulfo-cyanine
5 NHS ester from Lumiprobe. All reactions were carried out at
ambient temperature unless otherwise stated. Reactions were
monitored by thin-layer chromatography on commercially available
silica precoated aluminum-backed plates (Merck Kieselgel 60 F254).
Visualization was under UV light (254 and 366 nm), followed by
staining with ninhydrin or KMnO4 dips. Flash column chromatog-
raphy was performed using silica gel 60, 230−400 mesh particle size
(Sigma-Aldrich). NMR spectra were recorded on a Bruker-AV 400.
1H NMR spectra were recorded at 400.13 MHz and 13C NMR spectra
at 101.62 MHz. All 13C NMR are 1H broadband decoupled. Solvents
used for NMR analysis (reference peaks listed) were CDCl3 supplied
by Cambridge Isotope Laboratories Inc. (δH = 7.26 ppm, δC =
77.16). Chemical shifts (δ) are recorded in parts per million (ppm),
and coupling constants are recorded in Hz. The following
abbreviations are used to described signal shapes and multiplicities;
singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), dd
(doublet of doublets), ddd (double doublet of doublets), dtd (double
triplet of doublets), and multiplet (m). Processing of the NMR data
was carried out using the NMR software Topspin. LC-MS spectra
were recorded on a Shimadzu UFLCXR system coupled to an Applied
Biosystems API2000 and visualized at 254 nm (channel 1) and 220
nm (channel 2). LC-MS was carried out using a Phenomenex Gemini-
NX C18 110A, column (50 mm × 2 mm × 3 μm) at a flow rate 0.5
mL/min over a 5 min period (method A). All high resolution mass
spectra (HRMS) were recorded on a Bruker microTOF mass
spectrometer using MS electrospray ionization operating in positive
ion mode. RP-HPLC was performed on a Waters 515 LC system and
monitored using a Waters 996 photodiode array detector at
wavelengths between 190 and 800 nm. Spectra were analyzed using
Millenium 32 software. Semipreparative HPLC was performed using
YMC-Pack C8 column (150 mm × 10 mm × 5 μm) at a flow rate of
5.0 mL/min using a gradient method of 20−70% B over 21 min
(solvent A = 0.01% formic acid in H2O, solvent B = 0.01% formic acid
in CH3CN (method B)). Analytical RP-HPLC was performed using a
YMC-Pack C8 column (150 mm × 4.6 mm × 5 μm) and a
Phenomenex Gemini NX-C18 column (250 mm × 4.6 mm × 5 μm)
at a flow rate of 1.0 mL/min. Final products were one single peak and
>98% pure. The retention time of the final product is reported using a
gradient method of 10−90% solvent B in solvent A over 30 min.
(solvent A = 0.01% formic acid in H2O, solvent B = 0.01% formic acid
in CH3CN (method C)).
General Procedure 1: Synthesis of Fluorescent Conjugates. The
amine congener (as the di-HCl salt) was dissolved in DMF (0.5 mL),
treated with DIPEA (0.6 μL 3.7 mmol, 4 equiv) and then reacted with
BODIPY630/650−X-NHS (0.5 mg, 1 equiv), BODIPY-FL-X-NHS
(1 equiv, 0.5 mg), BODIPY-FL-NHS (1 equiv, 0.5 mg), sulfo-cyanine
5-NHS ester (0.8 mg, 1 equiv), Alexa Fluor 647-NHS (0.8 mg, 1
equiv), and HATU (1.7 mg, 1 equiv) prior reacting with
Figure 9. Displacement of 17 (50 nM) by unlabeled hA2AAR
antagonists ZM241385, SCH58261, SCH442416, and hA3AR
antagonist MRS1334 in HEK293G cells transiently expressing the
Nanoluc-hA2AAR. Blue and red bars represent the total BRET signal
of 17 in absence or presence of ZM241385 (10 μM), respectively.
The decrease in BRET ratio was monitored as a function of increasing
concentration of unlabeled antagonist. Each data point represents
mean value ± SEM of triplicate determinations in a single
representative experiment of n = 4 experiments.
Table 3. Binding Affinities (pKi) of Target hA2AAR
Antagonists Calculated from Cheng−Prusoff Analysis of the
Data Displayed in Figure 9
compd pKi (BRET binding assay) pKi (literature)
a
ZM241385 8.84 ± 0.09 8.80b
SCH58261 7.92 ± 0.10 8.30c
SCH442416 7.90 ± 0.10 8.38d
aReported binding affinities of target hA2AAR antagonists.
bValues
determined in radioligand binding experiments in CHO-hA2A and
HEK293-hA2A cells using [H
3] SCH58261.59,60 cValues determined in
radioligand binding experiments in CHO-hA2A and HEK293-hA2A
cells using [H3] SCH58261.59,60 dValues determined in HEK293-
hA2A using the radiolabeled agonist [
3H] CGS 21680.30 The data
measured through NanoBRET competition ligand binding assay are
means ± SEM of n = 4 experiments performed in triplicate.
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BODIPY630/650-carboxylic acid (2 mg). The resulting solution was
stirred at RT under the exclusion of light for 1−5 h. Upon completion
of the reaction monitored by LC-MS, the solution was concentrated
to dryness and the residue was dissolved in 1:1 CH3CN/H2O.
Purification by reverse phase-HPLC, followed by lyophilization,
afforded the pure fluorescent conjugate.
7-(2-Chloroethyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]-
triazolo[1,5-c]pyrimidin-5-amine (4). 2-Amino-4,6-dichloropyrimi-
dine-5-carbaldehyde (0.5 g, 2.6 mmol, 1 equiv) was dissolved in
anhydrous THF (20 mL). To the resulting mixture was added Et3N
(0.26 g, 2.86 mmol, 1.1 equiv) followed by 2-furoic hydrazide (0.36 g,
2.86 mmol, 1.1 equiv). The above mixture was heated to 70 °C for 3
h. The mixture was then evaporated in vacuo to give intermediate 2 as
yellow solid, which was used for the next reaction without further
purification. LC-MS m/z calcd for C10H9ClN5O3 [MH]
+: 282.04,
found 282.10, tR= 2.09 min (method A). To a solution of 2 (1 equiv)
in CH3CN/water (10:2.5 mL) was added 2-hydrazinoethanol (0.35
mL, 5.2 mmol, 2 equiv). The mixture was heated to reflux for 2.5 h.
The solution was allowed to cool at RT. Then 0.1 M HCl (5 mL) was
added to the reaction mixture. Afterward, the solution was evaporated
in vacuo to 5 mL and left overnight for a solid to appear. Water (10
mL) was added, and the solid was collected by filtration. The solid
was further washed with CH3CN and Et2O. The solid was dissolved
in MeOH, and the solution was evaporated azeotropically with
toluene to give the desired compound 3 which was used for the next
step without any further purification. LC-MS m/z calcd for
C12H14N7O3 [MH]
+: 304.12, found 304.10, tR = 0.61 min (method
A). Intermediate 3 (0.550 g, 1.8 mmol, 1 equiv) was dissolved in
POCl3 (4 mL). To the resulting mixture was added ZnBr2 (0.1 g).
The mixture was heated to 80 °C for 5 h. Then POCl3 was
evaporated, water (ice) added, and the resulting aqueous solution was
extracted with EtOAc. Organic layers were collected, dried over
Na2SO4 anhydrous, filtered, and evaporated to dryness. Purification
by flash column chromatography on silica gel using 2:1 EtOAc/
petroleum spirits gave a mixture of intermediates 4a and 4b as a pale-
yellow solid (0.11 g, yield 11%). LC-MS m/z calcd for C12H11ClN7O
[MH]+: 304.07, found 304.10; calcd for C12H10BrN7O [MH]
+:
348.02, found 348.10, tR = 2.50 min (method A).
1H NMR (DMSO-
d6) δ 8.23 (s, J = 1.0 Hz, 1H), 8.14 (brs, 2H), 7.95 (d, J = 1.8 Hz,
1H), 7.24 (d, J = 3.3 Hz, 1H), 6.74 (dd, J = 3.4, 1.8 Hz, 1H), 4.66 (t, J
= 6.2 Hz, 1H), 4.60 (t, J = 5.9 Hz, 2H), 4.09 (t, J = 5.9 Hz, 2H), 3.94
(t, J = 6.2 Hz, 1H).
2-(2-((tert-Butoxycarbonyl)amino)ethoxy)ethyl 4-Methylbenze-
nesulfonate (6). tert-Butyl (2-(2-hydroxyethoxy) ethyl) carbamate
(1 g, 4.87 mmol, 1 equiv) was dissolved in DCM (20 mL). To the
resulting mixture were added DIPEA (2.5 mL, 3 equiv), DMAP (5%
mol), and TsCl (1.85 g, 9.74 mmol, 1.3 equiv). The mixture was
stirred at RT overnight. The solution was concentrated under reduced
pressure to a volume of 5 mL. Purification by flash column
chromatography on silica gel using a gradient of 0 → 4% MeOH/
DCM gave the desired product (1.5 g, yield 86%). LC-MS m/z calcd
for C16H26NO6S [MH]
+: 360.15, found 360.10, tR = 2.51 min
(method A). 1H NMR (CDCl3) δ 7.80 (d, J = 8.0 Hz, 2H), 7.35 (d, J
= 7.96 Hz, 2H), 4.80 (brs, 1H), 4.16 (t, J = 4.1 Hz, 2H), 3.63 (t, J =
4.3 Hz, 2H), 3.45 (t, J = 4.4 Hz, 2H), 3.24 (q, J = 5.4 Hz, 2H), 2.45
(s, 3H), 1.45 (s, 9H). 13C NMR (CDCl3) δ 155.9, 145.0, 133.1,
129.9, 128.1, 79.4, 70.4, 69.2, 68.4, 40.3, 28.5, 21.7.
Benzyl 4-(4-Hydroxyphenyl)piperazine-1-carboxylate (8). Benzyl
chloroformate (0.793 mL, 5.6 mmol, 1 equiv) was added to a stirred
suspension of 4-(piperazin-1-yl) phenol (1.0 g, 5.6 mmol, 1 eq) and
K2CO3 (0.93 g, 6.7 mmol, 1.2 eq) in DMF (8 mL). Water was then
added, and the aqueous layer was extracted with EtOAc. The organic
layer was further washed with water (×3), dried over anhydrous
Na2SO4, filtered, and evaporated to dryness. Purification by flash
column chromatography on silica using 40% EtOAc/petroleum ether
gave the desired product (1.2 g, yield 66%). LC-MS m/z calcd for
C18H21N2O3 [MH]
+: 313.15, found 313.10, tR = 2.51 min (method
A). 1H NMR (CDCl3) δ 7.39−7.31 (m, 5H), 6.85 (d, J = 8.4 Hz 2H),
6.77 (d, J = 7.6 Hz, 2H), 5.17 (brs, 1H), 5.00 (s, 2H), 3.66 (t, J = 4.63
Hz 4H), 3.01 (m, 4H). 13C NMR (CDCl3) δ 155.1, 136.4, 128.4,
127.9, 127.8, 119.1, 115.8, 67.1, 50.9, 43.7 (two quaternary carbons in
the phenol not observed).
Benzyl 4-(4-(2-(2-((tert-Butoxycarbonyl)amino)ethoxy)ethoxy)-
phenyl)piperazine-1-carboxylate (9i). Compound 8 (0.36 g, 1.16
mmol) was dissolved in CH3CN (10 mL). K2CO3 (0.5 g) was
subsequently added to the reaction mixture, followed by compound 6
(0.416 g, 1.16 mmol, 1 equiv). The resulting mixture was heated to
100 °C and held at this temperature for 6 h. The reaction was allowed
to cool, Et2O was added, and the mixture was washed with 1 M
NaOH (×3). The organic layer was collected and evaporated to
dryness. Purification by flash column chromatography on silica using
60% EtOAc/petroleum ether gave the final product as an off-white
solid (0.2 g, yield 40%). LC-MS m/z calcd for C27H38N3O6 [MH]
+:
500.28, found 500.10, tR = 3.02 min (method A).
1H NMR (CDCl3)
δ 7.40−7.32 (m, 5H), 6.88 (s, 4H), 5.16 (s, 2H), 4.98 (brs, 1H), 4.07
(t, J = 4.3 Hz, 2H), 3.79 (t, J = 4.5 Hz, 2H), 3.66 (t, J = 4.8 Hz, 4H),
3.60 (t, J = 4.8 Hz, 2H), 3.34 (q, J = 4.6 Hz, 2H), 3.07−2.97 (m, 4H),
1.44 (s, 9H). 13C NMR (CDCl3) δ 155.4, 150.1, 136.4, 128.4, 127.9,
127.79, 115.3, 70.2, 69.4, 67.6, 67.1, 50.7, 43.7, 40.2, 28.2.
tert-Butyl (2-(2-(4-(Piperazin-1-yl)phenoxy)ethoxy)ethyl)-
carbamate (9ii). Compound 9i (0.2 g, 1 equiv) was dissolved in
EtOH (4 mL), and the resulting mixture was stirred at RT under a
nitrogen atmosphere. Pd/C 11% w/w was added to the reaction
mixture, and the flask was evacuated and replaced with a H2
atmosphere. The reaction was stirred at RT for 3 h. The completion
of the reaction was confirmed by TLC. The mixture was then filtered
through Celite, and the pad was washed with EtOH (40 mL) and
DCM (40 mL × 3). The filtrate was collected and concentrated under
reduced pressure to give the pure product as an off-white solid (0.12
g, yield 82%). LC-MS m/z calcd for C19H32N3O4 [MH]
+: 366.24,
found 366.10, tR = 2.12 min (method A).
1H NMR (CDCl3) δ 6.92−
6.84 (m, 4H), 5.00 (brs, 1H), 4.07 (t, J = 4.4 Hz, 2H), 3.79 (t, J = 4.4
Hz, 2H), 3.60 (t, J = 4.4 Hz, 2H), 3.47 (s, 1H), 3.33 (q, J = 4.8 Hz,
2H), 3.05 (s, 7H), 1.44 (s, 9H). 13C NMR (CDCl3) δ 156.1, 153.1,
146.5, 118.4, 115.5, 79.37, 70.5, 69.7, 67.9, 51.7, 46.2, 40.5, 28.5.
tert-Butyl (2-(2-(4-(4-(2-(5-Amino-2-(furan-2-yl)-7H-pyrazolo-
[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl)ethyl)piperazin-1-yl)-
phenoxy)ethoxy)ethyl)carbamate (10). tert-Butyl (2-(2-(4-(piper-
azin-1-yl)phenoxy)ethoxy)ethyl)carbamate (30 mg, 0.9 μmol, 1
equiv) and 4 (40 mg, 1.1 μM, 1 equiv) were dissolved in DMF
(0.5 mL) prior to the addition of DIPEA (4 equiv, 0.4 mL). The
resulting mixture was heated and held at 100 °C overnight.
Completion of the reaction was confirmed by TLC. The solution
was further dissolved in EtOAc and washed with water (×3). The
organic layer was collected and concentrated under reduced pressure.
Purification by flash column chromatography on silica using
DCM:MeOH (96:4) gave the pure compound as a pale-yellow
solid (12 mg, yield 19%). LC-MS m/z calcd for C31H41N10O5 [MH]
+:
633.33, found 633.10, tR = 2.12 min (method A).
1H NMR (CDCl3)
δ 8.18 (s, 1H), 7.53 (d, J = 1.8 Hz, 1H), 7.21 (d, J = 3.4 Hz, 1H),
6.88−6.81 (m, 4H), 6.56 (dd, J = 3.5, 1.8 Hz, 1H), 6.45 (brs, 2H),
5.01 (brs, 1H), 4.53 (t, J = 6.42 Hz, 2H), 4.05 (t, J = 3.72 Hz, 2H),
3.78 (t, J = 4.2 Hz, 2H), 3.59 (t, J = 4.1 Hz, 2H), 3.33 (q, J = 5.1 Hz),
3.14−3.07 (m, 4H), 2.98 (t, J = 6.00 Hz, 2H), 2.78−2.69 (m, 4H),
1.43 (s, 9H). 13C NMR (CDCl3) δ 156.7, 156.1, 152.9, 149.3, 148.3,
145.9, 145.5, 145.5, 144.7, 132.3, 118.1, 115.5, 112.7, 112.1, 97.4,
79.4, 70.5, 69.7, 67.9, 57.0, 53.4, 50.4, 45.3, 40.5, 28.5.
7-(2-(4-(4-(2-(2-Aminoethoxy)ethoxy)phenyl)piperazin-1-yl)-
ethyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]-
pyrimidin-5-amine (11). Compound 10 (12 mg, 1 equiv) was
dissolved in 4 M HCl in dioxane (1 mL). The completion of the
reaction was confirmed by TLC and LC-MS after 30 min. The solvent
was removed under reduced pressure and the compound was used in
the next synthetic step without further purification (10 mg,
quantitative 100%). LC-MS m/z calcd for C26H33N10O3 [MH]
+:
533.27, found 533.10, tR = 1.85 min (method A).
(E)-N-(2-(2-(4-(4-(2-(5-Amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e]-
[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)ethyl)piperazin-1-yl)phenoxy)-
ethoxy)ethyl)-6-(2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-5l4,6l4-
dipyrrolo[1,2-c:2′,1′-f ][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)-
acetamido)hexanamide (12). Following general procedure 1, amine
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congener 11 (0.5 mg, 1 equiv) was converted to the BODIPY630/
650-X conjugate 12. Purification by RP-HPLC (method B) gave, after
lyophilization, the title compound as a blue solid (1.1 mg 98%).
Analytical RP-HPLC tR = 15.48 min (method C), purity >98%.
HRMS (ESI-TOF) calcd for C55H59BF2N13O6S [M + H]
+:
1078.4488, found 1078.4508 and 1100.4307 [M + Na].
(E)-N-(2-(2-(4-(4-(2-(5-Amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e]-
[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)ethyl)piperazin-1-yl)phenoxy)-
ethoxy)ethyl)-2-(4-(2-(5,5-difluoro-7-(thiophen-2-yl)-5H-4l4,5l4-
dipyrrolo[1,2-c:2′,1′-f ][1,3,2]diazaborinin-3-yl)vinyl)phenoxy)-
acetamide (13). Following general procedure 1, amine congener 11
(1 equiv, 0.5 mg) was converted to the BODIPY630/650 conjugate
13. Purification by RP-HPLC (method B) gave, after lyophilization,
the title compound as a blue solid (1 mg, yield 56%). Analytical RP-
HPLC tR = 15.30 min (method C), purity >99%. HRMS (TOF ES
+)
calcd for C49H48BF2N12O5S [M + H]
+: 965.3574, found 965.3593.
N-(2-(2-(4-(4-(2-(5-Amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e]-
[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)ethyl)piperazin-1-yl)phenoxy)-
ethoxy)ethyl)-6-(3-(5,5-difluoro-7,9-dimethyl-5H-4l4,5l4-dipyrrolo-
[1,2-c:2′,1′-f ][1,3,2]diazaborinin-3-yl)propanamido)hexanamide
(14). Following general procedure 1, amine congener 11 (1 equiv, 0.5
mg) was converted to the BODIPY-FL-X conjugate 14. Purification
by RP-HPLC (method B) gave, after lyophilization, the title
compound as an orange solid, (1.2 mg, yield 70%). Analytical RP-
HPLC tR = 13.04 min (method C) purity >99%. HRMS (TOF ES
+)
calcd for C46H57BF2N13O5 [MH]
+: 920.4588, found 920.4660.
N-(2-(2-(4-(4-(2-(5-Amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e]-
[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)ethyl)piperazin-1-yl)phenoxy)-
ethoxy)ethyl)-3-(5,5-difluoro-7,9-dimethyl-5H-4l4,5l4-dipyrrolo[1,2-
c:2′,1′-f ][1,3,2]diazaborinin-3-yl)propanamide (15). Following gen-
eral procedure 1, amine congener 11 (1 equiv, 0.5 mg) was converted
to the BODIPY-FL conjugate 15. Purification by RP-HPLC (method
B) gave, after lyophilization, the title compound as an orange solid
(0.7 mg, yield 100%). Analytical RP-HPLC tR = 13.13 min (method
C), purity >99%. HRMS (TOF ES+) calcd for C40H46BF2N12O4
[MH]+: 807.3821, found 807.3820; calcd for C40H45BF2N12O4Na [M
+ Na]: 829.3640, found 829.3627.
1-(6-((2-(2-(4-(4-(2-(5-Amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e]-
[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)ethyl)piperazin-1-yl)phenoxy)-
ethoxy)ethyl)amino)-6-oxohexyl)-3,3-dimethyl-2-((1E,3E)-5-((E)-
1,3,3-trimethyl-5-sulfoindolin-2-ylidene)penta-1,3-dien-1-yl)-3H-
indol-1-ium-5-sulfonate (16). Following general procedure 1, amine
congener 11 (1 equiv, 0.5 mg) was converted to sulfo-cyanine-5
conjugate 16. Purification by RP-HPLC (method B) gave, after
lyophilization, the title compound as bright-blue solid (1.9 mg, yield
quantitative 100%) pure. Analytical RP-HPLC tR = 12.41 min
(method C) purity >99%. HRMS (TOF ES−) C58H68N12O10S2
[MH]−: calcd 1155.4550, found 1155.4547
3-(6-((2-(2-(4-(4-(2-(5-Amino-2-(furan-2-yl)-7H-pyrazolo[4,3-e]-
[1,2,4]triazolo[1,5-c]pyrimidin-7-yl)ethyl)piperazin-1-yl)phenoxy)-
ethoxy)ethyl)amino)-6-oxohexyl)-2-((1E,3E)-5-((E)-3,3-dimethyl-5-
sulfo-1-(3-sulfopropyl)indolin-2-ylidene)penta-1,3-dien-1-yl)-3-
methyl-5-sulfo-1-(3-sulfopropyl)-3H-indol-1-ium (17). Following
general procedure 1, amine congener 11 (1 eq., 0.5 mg) was
converted to the Alexa Fluor 647 conjugate 17. Purification by RP-
HPLC (method B) gave the title compound as bright-blue solid (1.8
mg quantitative 100%). Analytical RP-HPLC tR = 10.58 min (method
C) purity >99%. HRMS (TOF ES−) calcd for C62H76N12O16S4
[MH]−: 1372.4355, found 1372.4391; [M−2]−: calcd 685.2120,
found 685.2122.
Molecular Modeling of Preladenant. Docking of preladenant
to the high resolution hA2AAR crystal structure was performed using
Schrodinger software suite (release 2018-3). The 1.8 Å resolution
hA2AAR crystal structure was imported from the Protein Data Bank
(PDB 4EIY) and was prepared with the Protein Preparation Wizard
program. This involved removal of water molecules, cocrystallized
head groups, with the exclusion of the cocrystallized ligand
ZM241385, and the addition of hydrogen atoms. The H-bonding
network was optimized using PROPKA at pH = 7, and ultimately the
protein structure was energy minimized by using OPLS3 force field.
The docking site was defined with Glide Grid generation by using the
coordinates of the cocrystallized ligand ZM241385. Preladenant was
prepared for docking using LigPrep program. Molecular docking of
preladenant was performed using Glide with XP (extra precision)
mode and flexible ligand sampling without applying any restriction.
Ten poses were generated, and the highest glide scoring pose was
selected and modeled with PyMOL (version 2.2.0) to include key
binding residues and distances measurements.
Pharmacology: Material and Methods. Cell culture reagent
were purchased from Sigma Chemicals (Pool, Dorset, UK) except
Fetal Calf Serum (FCS), which was provided by PAA Laboratories
(Teddington, Middlesex, UK). G418 and Optimem were obtained
from Life Technologies (Paisley, UK). SNAP-Lumi4-Tb was obtained
by Cisbio Bioassays (Bagnols-sur-Cez̀e, France). All plates were
obtained from Corning Costar (Corning Incorporated, Corning, NY,
USA) unless otherwise stated. FuGENE transfection reagent and
furimazine were purchased from Promega (Southampton, UK).
ZM243185 was purchased from Tocris Bioscience (Bristol, UK).
All other chemical and reagents were purchased from Sigma-Aldrich
(Gillingham, UK)
Cell Culture. A CHO cell line stably expressing cAMP response
element-secreted placental alkaline phosphatase (CRE-SPAP) re-
porter gene and the human A2AR were generated as previously
described.55 CHO A2A CRE-SPAP cell lines were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM-F12) nutrient mix
supported by 10% heat-inactivated FCS and 2 mM L-glutamine.
HEK293 cells stably expressing NanoLuc-A1 and NanoLuc-A3 were as
described previously.63 To generate cells stably expressing the
NanoLuc-A2B HEK293 cells were stably transfected with pcDNA-
NanoLuc-A2B using FUGENE reagent, following the manufacturer’s
instructions, using 2:1 reagent:DNA ratio. Transfected cells were
selected using 1 μg/mL G418. Cells were cultured in DMEM
supplemented with 10% FCS. A SNAP-tagged HEK293 cell line
stably expressing the human SNAP-A2AR was generated by Dr. Laura
Kilpatrick, who performed the transfection, dilution cloning, and
isolation of a stable clone line. HEK293 cells expressing the
GloSensor cAMP bionsensor (HEK293G) were obtained from
Promega (United States). The HEK293 cell lines were maintained
in DMEM containing 10% FCS and 2 mM L-glutamine and were
grown to 70−80% confluency in 75 cm2 tissue culture flask before
splitting. All cell colonies were incubated at 37 °C, 5% CO2, and the
tissue culture procedures were performed in a class II laminar flow
hood using sterile conditions. Transient Transfection of NanoLuc-
tagged human A2AR in HEK293G cell line was carried out as follows:
72 h prior the experiment cells were removed from a confluent T75
flask and centrifuged. The pellet of cells was resuspended in 10 mL of
fresh complete DMEM. Afterward, each CORNING 10 mm × 20 mm
style dish was seeded with a density of 3 × 106 cells per dish in 10 mL
of complete DMEM. Then 48 h prior the experiment transfection of
the NanoLuc-tagged human A2AR in HEK 293G cell line was carried
out using a mixture of 6 μg DNA and 12 μL of FuGENE(1:2 ratio) in
880 μL of OptiMEM, followed by 5 min incubation at room
temperature to allow the DNA:FuGENE complex to form. After that
time, the entire mixture was carefully added to the CORNING dish
and incubated at 37 °C, 5%CO2 overnight. Then 24 h prior to the
experiment day, cells were removed from a confluent dish and
centrifuged. The pellet of cells was resuspended in 10 mL of fresh
DMEM, and the resulting NanoLuc-tagged hA2AR HEK293G cells
were seeded in white Thermo Scientific 96-well plates at a density of
32000 cells/well and grown in normal growth medium. Terbium
labeling of SNAP-tagged A2AAR cells: To terbium label the SNAP-
HEK293-A2AAR cells, cell culture media was removed from confluent
SNAP-HEK293-A2AAR cells contained in T175 cm
2
flasks, washed
once in DPBS, and then incubated with 100 nM of SNAP-Lumi4-Tb
in 1xLabMed buffer for 1 h at 37 °C, 5%CO2. Then the terbium
labeling reagent was removed, and cells were washed once with ice-
cold 15 mL of PBS. The cells were then removed from the wall of the
flask by scraping and centrifuged at 2000 rpm for 10 min, and the
resulting cell pellets were stored at −80 °C. Membrane preparations of
Terbium-labeled SNAP-HEK293-A2AAR cells: The following described
steps were conducted at 4 °C to circumvent receptor degradation.
Thawed pellets of cells were resuspended in PBS and homogenized
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using an electronical homogenizer, 10 × 2 s bursts. Homogenized
solution of cells was centrifuged at 1500 rpm for 20 min to remove
unbroken cells and nuclei. The supernatant was subsequently
centrifuged at 41415g for 30 min. The resulting pellet was
resuspended in 4 mL of PBS and fully homogenized. Protein
concentration was determined using a BCA protein assay and
membranes were stored at −80 °C until required. Before their use,
frozen membranes were thawed and suspended in HBSS buffer
Experiments. NanoBRET. HEK 293 cells were transiently trans-
fected to express NanoLuc-A2AAR. HEK293 cells expressing Nano-
Luc-AR were seeded in white Termo Scientific 96-well plates and
grown 24 h prior to the day of the experiment in normal growth
medium. Before the experiment, DMEM was replaced with HBSS.
For saturation and competition assays, the required concentration of
fluorescent ligands, and competing ligand was added at the same time.
Thereafter, plates were incubated for 2 h at 37 °C. After 2 h, 10 μM
furimazine (1:40 dilution; Promega) was added to each well. After 5
min of incubation at 37 °C, bioluminescence emission at two different
wavelenghts was measured using a PHERAstar FS plate reader (BMG
Labtech) at room temperature. The filter light emissions were read at
420 nm (80 nm bandpass) and 535 nm (60 nm bandpass) for BYFL-
labeled ligands and at 420 nm (80 nm bandpass) and >610 nm
(longapass) for the BY630/Cy5/AF647-labeled ligands. The raw
BRET ratio was calculated by dividing the >610 nm emission or 533
nm emission by the 420 nm emission. The term “raw BRET ratio”
refers to the unprocessed data as no background ratio has been
subtracted.
CRE-SPAP Assay. First, 48 h prior to the experiment day, CHO
CRE-SPAP A2AR cells were seeded onto clear 96-well plates and
subsequently serum starved 24 h before the experiment employing
DMEM-12 supplemented with 2 mM L-glutamine (serum-free
media). On the day of the assay, serum-free media was added to
the cells and the fluorescent compounds under investigation were
further added to the appropriate well at three concentrations (10, 100,
1000 nM), and the plates were incubated for 30 min at 37 °C, 5%
CO2. After 30 min, NECA was added at increasing concentrations and
the plates were incubated for further 5 h at 37 °C/5% CO2. Following
5 h incubation, the media was removed and replaced with 40 μL of
serum-free media. The plates were further incubated for 1 h at 37 °C/
5% CO2. Following 1 h incubation the plates were moved to an oven
at 65 °C for 30 min in order to degrade endogenous alkaline
phosphatases. The plates were then allowed to cool to room
temperature, and 100 μL of 5 mM of 4-p-nitrophenyl phosphate in
DEA buffer (100 nM diethanolamine; 280 nM NaCl; 0.5 nM MgCl2·
6H2O, pH = 9.85) were added in each well and the plates incubated
at 37 °C for 15 min. Once the yellow color has developed, the plates
were read on the Dynex MRX plate reader, which measured the
absorbance at 405 nm.
HTRF Binding Kinetic of BODIPY-630/650-X Conjugate 12. To
determine the binding kinetics of fluorescent conjugate 12, HEK293
SNAP-hA2AAR cell membranes were diluted to the required
concentration (10 μg/well) in HBSS buffer containing saponin (1
mg/mL) and added in white Thermo Scientific 96-well microplates.
Fluorescent conjugate 12 was added simultaneously at four different
concentrations in the presence and absence of 10 μM ZM241385 to
define nonspecific binding. The plates were read immediately: each
well was read every 30 s for 60 min. TR-FRET signals were acquired
in a PHERAstarFS plate reader (BMG Labtech) equipped with a
homogeneous time resolved fluorescence module with excitation at
337 nm and emission 620 and 655 nm. HTRF ratios were calculated
by dividing the acceptor signal (655 nm) by the donor signal (620
nm).
Confocal Microscopy. Cell were grown to 70−80% confluence in
eight-well borosilicate chambered-coverglass plates (Nunc Nalgene,
Rochester, NY) precoated with poly-D-lysine 48 h before imaging. On
the day of the experiment, medium was removed and the cells were
labeled for 30 min at 37 °C with 0.2 μM SNAP AF488 or AF647 as
required in fresh HBSS [HEPES Balanced Salt Solution (HBSS), 25
mM HEPES, 10 mM glucose, 145 mM NaCl, 5 mM KCl, 1 mM
MgSO4, 2 mM sodium pyruvate, 1.3 mM CaCl2 at pH 7.4]. After
washing twice with HBSS, the cells were treated with or without 1 μM
ZM241385 for 30 min at 37 °C. Following the incubation step, the
fluorescent ligands under investigation were added to the appropriate
wells at the required concentrations. Live cell imaging was performed
at 37 °C using a Zeiss LSM 710 laser scanning confocal microscope
fitted with a Zeiss Plan-Neofluar 40 × 1.2 NA water immersion
objective. A 633 nm HeNe laser was used for the excitation of the
BODIPY630/650, Cy5 and AF647 representative fluorophores, and A
488/561/633 dichroic, and the emission was detected using 650 nm
LP filter. A 488 nm HeNe laser was used for BODIPY-FL
fluorophores series and the emission was detected using LP575 filter.
The pinhole diameter (1 Airy Unit; 1.1 μm optical slice), laser power
and gained remained constant in all the experiments. Images were
processed in Zeiss Zen 2 (blue edition) software, and linear
adjustments to the brightness and contrast have been applied equally
across all the images.
Data Analysis. All data are represented as mean ± SEM of n
experiments performed in triplicate. The n refers to the number of
separate experiments. A separate experiment requires cells plated from
a separate flask and separate drug dilution used throughout the
experiment. The data were presented and analyzed using Prism
software (GraphPad Prism 7) and Excel.
Reporter Gene SPAP Assay. Antagonism by unlabeled and labeled
(fluorescent) ligands of the CRE-reporter gene response (SPAP,
secreted placental alkaline phosphatase) to NECA in CHO cells
expressing the human A2A AR was analyzed. For each concentration of
the antagonists, the ratio (DR, dose ratio) of NECA concentrations
required to produce the same sized response in the presence and
absence of the antagonist was determined. The antagonist dissociation
constant (KB) was determined by globally fitting the data to the Schild
equation:
− = [ ] − Klog(DR 1) log( B ) log B
where DR (dose ratio) is the ratio of the agonist concentration
required to stimulate an identical response in the presence or absence
of antagonist, [B]. KB represents the equilibrium dissociation constant
of the antagonist.
NanoBRET Assay. Total and nonspecific saturation binding curves
were fitted simultaneously using the following equation:
= [ ]
[ ] +
+ [ ] +B
K
M CBRET ratio
B
B ( )
Bmax
D
where Bmax is the maximal response, [B] is the concentration of
fluorescent ligand in nM, KD is the equilibrium dissociation constant
in nM, M is the slope of the nonspecific binding component, and C is
the intercept with the y axis.
The competition binding curves were fitted to the following
equation:
= − × [ ]
[ ] +
uninhibited specific binding 100
100 A
A (IC )50
where [A] is the concentration of competing drug and the IC50 is the
molar concentration of ligand required to inhibit 50% of the specific
binding of 50 nM Alexa Fluor 647-bearing probe 17.
The Cheng−Prusoff equation was used to correct fitted IC50 values
to Ki values:
−
+ [ ]
K
IC
1
K
i
50
L
D
where [L] is the concentration of fluorescent ligand in nM and KD is
the dissociation constant of fluorescent ligand in nM. The calculated
KD values used were as calculated from the saturation binding
experiments.
HTRF Binding Kinetic Assay. From association binding kinetics,
nonspecific binding was determined for each concentration of the
fluorescent conjugate at each time point by adding 10 μM of
ZM241385, and this was subtracted from total binding to obtain
specific binding measurements. The association rate (kon) in M
−1
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min−1 and dissociation rate (koff) in min
−1 constants were calculated
from specific binding following equation:
= −
[ ]
k
k k
Lon
obs off
where [L] is the concentration of the fluorescent conjugate in M, and
kobs is calculated from the global fitting of the data to the following
exponential association function:
= − −Y Y e(1 k tmax obs
where Y is the specific binding at time t, Ymax represents the specific
binding at infinite time (t), and kobs is the rate constant for the
observed rate of association.
The kinetic equilibrium dissociation constant (KD) was determined
from the data using the following equation:
=K k
kD
off
on
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